Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics

Published:2019-08 Issue:2 Volume:96 Page:489-504
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Mayer Gert J.,Wanner Christoph,Weir Matthew R.,Inzucchi Silvio E.,Koitka-Weber Audrey,Hantel Stefan,von Eynatten Maximilian,Zinman Bernard,Cherney David Z.I.

Funder

Boehringer Ingelheim

Canadian Institutes of Health Research

Eli Lilly and Company

University Health Network

Juvenile Diabetes Research Foundation Canada

University of Toronto

Novo Nordisk

AstraZeneca

AbbVie

Canadian Diabetes Association

Publisher

Elsevier BV

Subject

Nephrology

Reference40 articles.

1. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N Engl J Med,2016

2. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

3. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

4. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

5. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications;Heerspink;Circulation,2016

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of age on eGFR dynamics following sodium-glucose cotransporter 2 inhibitor therapy: A real-world study;Diabetes Research and Clinical Practice;2024-08

2. Kidney outcomes with SGLT2is for type 2 diabetes patients: does background treatment with metformin or RASis matter?;Frontiers in Endocrinology;2024-06-27

3. Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect;Kidney International;2024-06

4. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

5. Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review;Consilium Medicum;2024-05-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3